# neovascular Age-related Macular Degeneration FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/neovascular-age-related-macular-degeneration

> 2 upcoming FDA catalysts in neovascular Age-related Macular Degeneration: otx-tki (OCUL) on Jan to Apr 2027 (topline data readout); otx-tki (OCUL) on January 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS | neovascular Age-related Macular Degeneration | scheduled | "Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm)) |
| December 17, 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS | neovascular Age-related Macular Degeneration | completed, positive | "Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-na&iuml;ve patients with neovascular age-related macular degeneration (nAMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416dex991.htm)) |
| April 2026 | [Otx-tki (axitinib implant) primary completion](https://sec-api.dev/pdufa/otx-tki-axitinib-implant) | OCUL | Neovascular Age-Related Macular Degeneration | delayed | "NCT06223958 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-29 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06223958)) |
| Jan to Apr 2027 | [Otx-tki topline data readout](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-related Macular Degeneration | scheduled | "NCT06495918 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06495918)) |
| January 2027 | [Otx-tki primary completion](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-related Macular Degeneration | scheduled | "NCT06495918 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06495918)) |

## Drugs

- [TH103](https://sec-api.dev/pdufa/th103) (KLRS)
- [Otx-tki (axitinib implant)](https://sec-api.dev/pdufa/otx-tki-axitinib-implant) (OCUL)
- [Otx-tki](https://sec-api.dev/pdufa/otx-tki) (OCUL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/neovascular-age-related-macular-degeneration.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "neovascular Age-related Macular Degeneration FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/neovascular-age-related-macular-degeneration

```bibtex
@misc{secapidev_indications_neovascular_age_related_macular_degeneration_20261116,
  title        = {neovascular Age-related Macular Degeneration FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/neovascular-age-related-macular-degeneration}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_neovascular_age_related_macular_degeneration_20261116","title":"neovascular Age-related Macular Degeneration FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/neovascular-age-related-macular-degeneration","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
